Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of UCB BIOPHARMA is 1.2% (low). The company has been active since 2013 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Based on State Gazette and CBE data.
Financials
No processed annual-account figures available.
To financials
People & board
12 mandates
5
active directors
Henry, AlistairDirectorDenelle J. Waynick JohnsonDirectorSandrine DUFOURDirector+9 in history
All directors & mandates Publicationslatest 02-01-2026
79
publications in the State GazetteArticles of association amendedAll publications & acts Network & structure
1
connected companySee network & structure
Connections
1 connected companyParent · 351 subsidiaries · 5 locations
Control→
Trust signals
3 signalsEstablished
Founded in 2013 — 12 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone1.2%
Low
0%0,5%1,5%4%10%≥25%
Higher-failure-rate region
+Multiple establishment units
+Lower-failure-rate sector
−
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Company registry (CBE)
Crossroads BankActivities
Vervaardiging van geneesmiddelen21201Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110
Primary activity highlighted.
Names & trade names
| Legal nameFR | UCB BIOPHARMA |
Registered office
Researchdreef 60
1070 Anderlecht, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.